16.30-17.00
Coffee and exhibition (sponsors Novartis and Beigene)
17.00
Welcome, Chair of the Foundation’s Board, Prof. Riitta Lassila
17.05
ASH Presentations
Hanna Duàn
Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
Jonas Bouhlal
Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity
Riitta Lassila
Low-Molecular-Weight Heparin Benefited Outpatients with High Risk of Venous Thromboembolism Early in COVID-19 Pandemics
Miro Nylén
Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas
Joseph Saad
Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
Henri Sundquist
Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Ankita Srivastava
Deciphering Variability in Light Chain Amyloidosis and Amyloidosis with Co-Occurring Multiple Myeloma by Single-Cell RNA Sequencing
Hannu Mönkkönen
The Best from ASH – by Novartis
Blood Disease Research Foundation supports no travel or accommodation. Sponsors of the meeting are Novartis and Beigene.
Welcome!